Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Correction: Field, M. et al. AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients.

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Snyder D, Foster K.

Toxins (Basel). 2019 Feb 13;11(2). pii: E115. doi: 10.3390/toxins11020115.

2.

AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), and IncobotulinumtoxinA (Xeomin®) Neurotoxin Content and Potential Implications for Duration of Response in Patients.

Field M, Splevins A, Picaut P, van der Schans M, Langenberg J, Noort D, Foster K.

Toxins (Basel). 2018 Dec 13;10(12). pii: E535. doi: 10.3390/toxins10120535. Erratum in: Toxins (Basel). 2019 Feb 13;11(2):.

3.

The Expanding Therapeutic Utility of Botulinum Neurotoxins.

Fonfria E, Maignel J, Lezmi S, Martin V, Splevins A, Shubber S, Kalinichev M, Foster K, Picaut P, Krupp J.

Toxins (Basel). 2018 May 18;10(5). pii: E208. doi: 10.3390/toxins10050208. Review.

4.

The denatured state under native conditions: a non-native-like collapsed state of N-PGK.

Reed MA, Jelinska C, Syson K, Cliff MJ, Splevins A, Alizadeh T, Hounslow AM, Staniforth RA, Clarke AR, Craven CJ, Waltho JP.

J Mol Biol. 2006 Mar 24;357(2):365-72. Epub 2006 Jan 11.

PMID:
16430920

Supplemental Content

Loading ...
Support Center